University of Hertfordshire

From the same journal

By the same authors

  • Diana Gorog
  • Ying X. Gue
  • Tze-Fan Chao
  • Laurent Fauchier
  • Jose Luis Ferreiro
  • Kurt Huber
  • Stavros V Konstantinidis
  • Deirdre A Lane
  • Francisco Marin
  • Jonas Oldgren
  • Tatjana Potpara
  • Vanessa Roldan
  • Andrea Rubboli
  • Dirk Sibbing
  • Hung-Fat Tse
  • Gemma Vilahur
  • Gregory Y H Lip
View graph of relations
Original languageEnglish
Number of pages28
JournalThrombosis and haemostasis
Early online date22 Mar 2022
DOIs
Publication statusE-pub ahead of print - 22 Mar 2022

Abstract

Whilst there is a clear clinical benefit of oral anticoagulation (OAC) in patients with atrial fibrillation (AF) and venous thromboembolism (VTE) in reducing the risks of
thromboembolism, major bleeding events (especially intracranial bleeds) may still occur and be devastating. The decision for initiating and continuing anticoagulation is often based on a careful assessment of both thromboembolism- and bleeding- risk. The more common and
validated bleeding risk factors have been used to formulate bleeding risk stratification scores, but thromboembolism and bleeding risk factors often overlap. Also, many factors that increase bleeding risk are transient and modifiable, such as variable INR values, surgical procedures, vascular procedures, or drug-drug and food-drug interactions. Bleeding risk is also not a static ‘one off’ assessment based on baseline factors but is dynamic, being influenced by ageing, incident comorbidities and drug therapies.
In this executive summary of our Consensus Document, we comprehensively review the published evidence and propose a consensus on bleeding risk assessments in patients with AF and VTE, with a view to summarising ‘best practice’ when approaching antithrombotic therapy in these patients. We address the epidemiology and size of the problem of bleeding risk in AF and VTE, and review established bleeding risk factors and summarise definitions of bleeding. Patient values and preferences, balancing the risk of bleeding against thromboembolism are reviewed, and the prognostic implications of bleeding are discussed.
We propose consensus statements that may help to define evidence gaps and assist in everyday clinical practice.

Notes

© The Author(s) 2022. Published on behalf of the European Society of Cardiology. All rights reserved. This is the accepted manuscript version of an article which has been published in final form at https://doi.org/10.1093/europace/euac020

ID: 27448071